NCT04139902 2025-10-15Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in MelanomaUniversity of PittsburghPhase 2 Active not recruiting48 enrolled